Madison, WI,– Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent -a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

• Superior DNA Delivery—Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.

• Formulated for Low Cellular Toxicity—Maintain cell density and reduce experimental biases due to toxicity.

• Scientifically Proven—Developed by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale to breast cancer research.